The estrogen receptor (ER) is the most useful marker currently available for breast cancer, being used both to predict response to therapy and assess prognosis. Recently, a new form of the ER, known as ER-beta, was identified. In this preliminary study we show that ER-beta mRNA was expressed less frequently in breast cancers than ER-alpha. ER-alpha but not ER-beta levels correlated with ER protein as determined by ELISA. We conclude that ER-beta is expressed in approximately 50% of breast cancers but it does not appear to be detected by a widely available ELISA.
GehringU.Steroid hormone receptors: biochemistry, genetics and molecular biology.TIBS1987; 12: 399–402.
2.
KuiperG.G., EnmarkE., Pelto-HuikkoM.Cloning of a novel receptor expressed in rat prostate and ovary.Proc Natl Acad Sci USA1996; 93: 5925–30.
3.
KuiperG.G., GustafssonJ.A.The novel estrogen receptor-beta subtype: potential role in the cell and promoter-specific actions of estrogens and anti-estrogens.FEBS Lett1997; 410: 87–90.
4.
McGuireW.L.Steroid hormone receptors in breast cancer treatment strategy.Recent Prog Horm Res1980; 36: 135–56.
5.
DuffyM.J.Biochemical markers as prognostic indices in breast cancer.Clin Chem1990; 36: 188–91.
6.
DotzlawH., LeygueE., WatsonP.H.Expression of estrogen receptor-β in human breast tumors.J Clin Endocrinol Metab1997; 82: 2371–4.
7.
LeygueE., Dotzlaw WatsonP.H.Altered estrogen receptor-α and β mRNA expression during breast tumorigenesis.Cancer Res1998; 58: 3197–201.
